Non-Hodgkin’s Lymphoma Pipeline Assessment – FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies Involved

August 31 21:40 2022
Non-Hodgkin's Lymphoma Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies Involved
Delveinsight Business Research LLP
DelveInsight’s analysis depicts a robust Non-Hodgkin’s Lymphoma Pipeline with 150+ active players in the domain working on 150+ pipeline therapies. The dynamics of the Non-Hodgkin Lymphoma market are anticipated to change in the coming years, owing to the launch of emerging therapies.

Non-Hodgkin’s Lymphoma Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin’s Lymphoma Market. 

The Non-Hodgkin’s Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Non-Hodgkin's Lymphoma Pipeline Analysis

Non-Hodgkin’s Lymphoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin’s Lymphoma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Non-Hodgkin’s Lymphoma Treatment.

  • Non-Hodgkin’s Lymphoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Non-Hodgkin’s Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-Hodgkin’s Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report –

Non-Hodgkin’s Lymphoma Therapeutics Landscape

In order to provide better relief for the symptoms and improve the Quality of life (QoL) of patients with NHL, globally, major Pharma giants are thoroughly working toward developing new treatment therapies for Non-Hodgkin Lymphoma.

Key companies in the Non-Hodgkin Lymphoma Therapeutics market include:

Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics and others.

Non-Hodgkin Lymphoma therapies covered in the report include:

Obinutuzumab, Abemaciclib, Ibrutinib, CPI 818, Devimistat, Venetoclax, Loncastuximab tesirine, LAM-002, HMPL-523, Venetoclax, Ibrutinib, Naratuximab emtansine, NKTR-255, LOXO-305, LAM–002, CNCT19, GB226, BI-1206, CAR-CD19 T Cells, AUTO4, TT11, CC-99282, AB-205, and several others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Non-Hodgkin’s Lymphoma Current Treatment Patterns

4. Non-Hodgkin’s Lymphoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-Hodgkin’s Lymphoma Late Stage Products (Phase-III)

7. Non-Hodgkin’s Lymphoma Mid-Stage Products (Phase-II)

8. Non-Hodgkin’s Lymphoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Hodgkin’s Lymphoma Discontinued Products

13. Non-Hodgkin’s Lymphoma Product Profiles

14. Key Companies in the Non-Hodgkin’s Lymphoma Market

15. Key Products in the Non-Hodgkin’s Lymphoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Non-Hodgkin’s Lymphoma Unmet Needs

18. Non-Hodgkin’s Lymphoma Future Perspectives

19. Non-Hodgkin’s Lymphoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Other Trending Healthcare Reports by DelveInsight

Age-related Vision Dysfunction Market
“Age-related Vision Dysfunction Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Age-related Vision Dysfunction Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States